$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
克唑替尼治疗ROS1重排非小细胞肺癌患者
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK阳性NSCLC的疗效
2025-10-19 11:44:20
Check Details
艾乐替尼治疗ALK阳性非小细胞肺癌效果显著
2025-10-19 11:44:20
Check Details
非小细胞肺癌靶向药物吉非替尼
2025-10-19 11:44:20
Check Details
奥希替尼为EGFR-TKI耐药患者带来希望
2025-10-19 11:44:20
Check Details
艾乐替尼ALK+NSCLC的一线治疗药物
2025-10-19 11:44:20
Check Details
色瑞替尼可延长ALK基因突变患者生存期
2025-10-19 11:44:20
Check Details
阿法替尼可降低肺癌进展风险26%
2025-10-19 11:44:20
Check Details
克唑替尼作为ALK MET抑制剂——治疗肺癌的药物
2025-10-19 11:44:20
Check Details
奥希替尼EGFR敏感突变阳性患者的一线用药
2025-10-19 11:44:20
Check Details
克唑替尼用于ALK重排阳性非鳞状NSCLC的疗效
2025-10-19 11:44:20
Check Details
吉非替尼与化疗相比延长患者的生存期
2025-10-19 11:44:20
Check Details
1
2
...
3004
3005
3006
3007
3008
3009
3010
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
2
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
3
Vemurafenib (Zelboraf) Complete Medication Guide
4
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
5
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
6
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
7
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
8
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
9
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
10
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
11
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
12
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity